8-K: Mangoceuticals Grants CEO 2M Options, Awards Stock to Execs

Mangoceuticals, Inc. announced significant equity compensation for its CEO and other key executives and directors, including 2 million stock options for CEO Jacob D. Cohen.

Summary

• The Board of Directors of Mangoceuticals, Inc., with the recommendation of the Compensation Committee, approved several equity grants effective September 9, 2025.
• CEO Jacob D. Cohen received 500,000 shares of common stock as a bonus for services rendered during 2025, which vested immediately upon issuance.
• Mr. Cohen was also granted options to purchase 2,000,000 shares of common stock, with a 10-year term expiring on September 9, 2035.
• The options granted to Mr. Cohen have an exercise price of $2.30 per share, which was the closing sales price of the company's common stock on the grant date.
• The CEO's options vest over 18 months: 500,000 options vested upon grant, and 500,000 options will vest on the 6th, 12th, and 18th month anniversaries of the grant date, subject to his continued service.
• Full vesting of Mr. Cohen's options will occur upon termination by the company without cause, by Mr. Cohen for good reason, or upon a change of control.
• CFO Eugene M. Johnston received 100,000 shares of common stock as a bonus for services rendered during 2025, which vested immediately.
• Board members Kenny Myers, Alex Hamilton, and Lorraine DAlessio each received 100,000 shares of common stock for services rendered during 2025, which vested immediately.
• All grants were made under the Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Plan.

Sentiment

Score: 6

Explanation: The grants are a positive for management and directors, aligning their interests with shareholders. However, the potential for future dilution from the options and immediate vesting of a significant number of shares introduces a moderate negative for existing shareholders. It's a standard compensation event, not indicative of extraordinary performance or distress.

Positives

• The equity grants align the interests of the CEO, CFO, and non-executive directors with those of shareholders, incentivizing long-term value creation.
• The compensation package recognizes and rewards key leadership for their contributions and services rendered to the company during 2025.
• The exercise price for the CEO's options was set at the closing market price on the grant date ($2.30 per share), indicating a fair market value grant.
• Immediate vesting of 900,000 shares and 500,000 options provides immediate incentive and recognition for the recipients.

Negatives

• The issuance of 900,000 shares and options for an additional 2,000,000 shares represents potential dilution for existing shareholders.
• The immediate vesting of a significant portion of the equity awards could lead to immediate selling pressure if recipients choose to liquidate their holdings.
• The full vesting clause for the CEO's options upon certain termination events or a change of control could result in substantial costs to the company under those circumstances.

Risks

• Dilution Risk: The issuance of new common stock and the potential exercise of 2,000,000 options will increase the total number of outstanding shares, which could dilute the ownership percentage and earnings per share for existing shareholders.
• Tax Consequences for Optionees: Recipients of options may face complex tax obligations, particularly if the Internal Revenue Service determines the options were granted with an exercise price less than the fair market value, potentially leading to additional taxes and penalties under Code Section 409A.
• Service Contingency: The vesting of the CEO's options is contingent on his continued service, meaning unvested options could be forfeited if his employment terminates under conditions not covered by the accelerated vesting clauses.
• Market Price Volatility: The value of the granted shares and the potential profitability of the options are directly tied to the company's stock price, exposing recipients to market fluctuations.

Future Outlook

The vesting schedule for the CEO's options over 18 months is contingent on his continued service, indicating an expectation of his long-term engagement with the company. The grants are for services rendered and to be rendered, suggesting a forward-looking incentive structure aimed at retaining key leadership and aligning their performance with future company success.

Management Comments

• The Board of Directors of Mangoceuticals, Inc., with the recommendation of the Compensation Committee, approved the grant of shares and options in consideration for services rendered and to be rendered to the Company as Chief Executive Officer and other roles during 2025.

Industry Context

Equity compensation, including stock options and restricted stock, is a standard practice across various industries, particularly in growth-oriented sectors like biotechnology or pharmaceuticals, to attract, retain, and incentivize key talent. These grants are a common mechanism for aligning management's interests with long-term shareholder value creation, a fundamental objective in corporate governance.

Comparison to Industry Standards

• The grant of stock and options to executives and non-executive directors is a common compensation strategy, comparable to practices at many publicly traded companies, including those in the biotech sector like Moderna (MRNA) or BioNTech (BNTX), which frequently use equity to incentivize leadership.
• A 10-year term for stock options is standard in the industry, aligning with typical grant terms observed at technology and healthcare firms.
• The vesting schedule for the CEO's options, with immediate vesting of a portion and the remainder over 18 months, is relatively short compared to the more common 3-4 year vesting schedules at larger, more established companies, but can be a strategy in smaller or rapidly developing firms to provide quicker incentives.
• Setting the option exercise price equal to the closing market price on the grant date is a standard practice for 'at-the-money' options, which is generally accepted and avoids immediate taxable income for the recipient at the time of grant.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience potential dilution from the issuance of new shares and the exercise of options, but the grants are intended to align management's interests with long-term shareholder value creation.
• Executives and Directors: Directly benefit from increased equity ownership and potential future financial gains, serving as a strong incentive for performance and retention.
• Employees: While specific to executives and directors, a robust equity plan can signal a company's commitment to performance-based compensation, potentially boosting morale and retention across the organization.

Next Steps

• Continued service of the CEO is required for the full vesting of his stock options over the 18-month period.
• Recipients may choose to exercise their options or sell their granted shares in the future, subject to market conditions and any applicable trading restrictions.

Key Dates

Recommendation

The filing details routine, albeit substantial, equity compensation for key executives and directors. While the grants align management incentives with shareholder interests, the potential for dilution from the issuance of new shares and the exercise of 2 million options warrants caution. There are no new operational or financial performance details to suggest a strong buy or sell, making a 'hold' recommendation appropriate as investors assess the long-term impact of these incentives against potential dilution.

Keywords

Mangoceuticals, MGRX, Equity Plan, Stock Options, Common Stock, Executive Compensation, Board Compensation, CEO Bonus, Dilution, Corporate Governance, SEC Filing, 8-K